Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results from an in vivo study of CRV431 in a diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND). Hepion’s CRV431 administered orally and once...

Coridea and Deerfield Management have established Deerfield Device Design and Development Catalyst to advance medtech innovation and accelerate the formation of commercial companies. Coridea is a medtech incubator;...

Closely held Azura Ophthalmics of Israel  announced positive topline results from a Phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). The company’s...

Closely-held KA Imaging will present a poster on results from a study examining the feasibility of lateral chest dual-energy subtraction radiography using a stacked single-exposure multi-layer x-ray detector at the...

Closely-held Notch Therapeutics closed an $85-million series A financing to support continuing development of its portfolio of induced pluripotent stem cell (iPSC)-derived T-cell therapeutic product candidates and...

MD Anderson Cancer Center has completed patient dosing in the second cohort of a Phase 1b investigator-initiated trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, for the targeted treatment of solid tumor...

Closely held Kardium raised $115-million in a new financing round led by Fidelity Management & Research, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates. The new...